BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Vista Partners Updates Coverage on Ohr Pharmaceutical (OHRP); Target Price $3.50


10/17/2012 9:20:42 AM

SAN FRANCISCO, CA--(Marketwire - October 17, 2012) -

Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month target price of $3.50. Ross Silver, Principal Analyst at Vista Partners, stated, "OHR is developing two drugs: Squalamine Eye Drops, in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD) & OHR/AVR 118, in a Phase 2 trial, for the treatment of Cancer Cachexia. Therapies for Wet-AMD such as ranibizumab (Lucentis®) sold by Genentech (acquired by Roche), as well as Regeneron's aflibercept (Eylea®) intravitreal injections, have become the market leaders in treating Wet-AMD and both therapies combined could garner approximately $5B in revenues in 2012. OHR's Wet-AMD clinical candidate Squalamine eye drops, in a Phase 2 trial, seems to present a significant advantage relative to the aforementioned therapies considering the delivery method which is self-administered eye drops. Both Lucentis® and Eylea® require an injection into the back of the eye. Earlier this year, Squalamine Eye Drops were awarded Fast Track designation by the U.S. Food and Drug Administration (FDA) for its potential treatment of Wet-AMD. The Squalamine Eye Drop program has the potential to create a monumental shift in the way patients are treated for Wet-AMD."

To download a FREE copy of the Ohr Pharmaceutical, Inc. research report, please visit http://www.vistapglobal.com and click the "Download" icon to gain access to the report.

About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more...

Disclaimer & Disclosure:
We encourage readers to view a complete list of disclaimers and disclosures on our website www.vistapglobal.com.


Contact:
Vista Partners
877.215.4813
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->